MLKL and bacterial infectious disease: None of these genes had to date been associated with AIEC infection or used as a target to inhibit bacterial infection, although PIK3cb and MLKL had previously been suggested as targets for therapeutic intervention in IBD, while MAP2K1 has a currently approved kinase inhibitor targeted towards it for IBD treatment [25, 27].